Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic announced a significant board expansion and appointment in an 8-K filing dated June 28, 2025. The Board of Directors increased from 10 to 11 members with the appointment of Dr. Joon Lee, effective June 18, 2025.
Key details of the appointment:
- Dr. Lee will serve on the Science and Technology Committee and the Compensation and Talent Committee
- Will receive standard non-employee director compensation including annual cash retainer and equity grants as outlined in the August 2024 proxy statement
- No special arrangements or understandings influenced the appointment
- No reportable transactions under Item 404(a) of Regulation S-K between Dr. Lee or immediate family and the company
The appointment was formally announced via press release on June 23, 2025. The filing was executed by Ivan K. Fong, Executive Vice President, General Counsel and Secretary.
Medtronic plc (MDT) has delivered a routine notice to the U.S. Securities and Exchange Commission stating that its Annual Report on Form 10-K for the fiscal year ended April 25, 2025, filed on June 20, 2025, contains disclosure made under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act. The letter, signed by Vice President, Global Controller and Chief Accounting Officer Denise L. Blomquist, fulfills the statutory requirement to alert the SEC of any Iran-related activities discussed in the 10-K. No quantitative details or descriptions of the underlying transactions are provided in this notice, leaving investors to consult the full 10-K for specifics.
Medtronic filed its FY2025 10-K report, detailing operations across four major segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The company maintains a strong international presence with significant operations in both US and international markets.
Key operational highlights include:
- Strategic focus on enterprise excellence and simplification restructuring programs
- Continued investment in research and development across all segments
- Notable divestiture of the Ventilator Product Line in February 2024
- Completion of the Renal Care Solutions/Mozarc transaction in April 2023
Financial structure includes various senior notes due between 2025-2053 with interest rates ranging from 0% to 4.15%. The company maintains a diversified debt portfolio in multiple currencies (USD, EUR, JPY). Significant emphasis on fair value measurements and risk management, particularly in Level 3 assets including revenue and product development milestones.